ES2637024T3 - Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1 - Google Patents

Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1 Download PDF

Info

Publication number
ES2637024T3
ES2637024T3 ES10747897.6T ES10747897T ES2637024T3 ES 2637024 T3 ES2637024 T3 ES 2637024T3 ES 10747897 T ES10747897 T ES 10747897T ES 2637024 T3 ES2637024 T3 ES 2637024T3
Authority
ES
Spain
Prior art keywords
captopril
group
pharmaceutical composition
arb
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10747897.6T
Other languages
English (en)
Inventor
Angelo Guglielmotti
Beatrice Garrone
Alessandro Ble'
Giuseppe Biondi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Application granted granted Critical
Publication of ES2637024T3 publication Critical patent/ES2637024T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Abstract

Composición farmacéutica, que comprende: (a) el ácido 2-((1-bencil-3-indazolil)metoxi)-2-metilpropiónico que presenta la fórmula estructural siguiente: (b) por lo menos uno de entre (i) un agente hipotensor seleccionado de entre unos inhibidores de ACE, ARB y CCB, y/o (ii) un agente reductor del colesterol seleccionado de entre unos derivados de estatina, o cualquier sal farmacéuticamente aceptable y éster del mismo, y (c) por lo menos un vehículo farmacéuticamente aceptable, en la que dicho inhibidor de ACE se selecciona de entre el grupo que consiste en alacepril, altiopril calcio, benzoil-captopril, captopril, captopril-cisteína, captopril-glutatión, ceronapril, converstatina, enalapril, enalaprilato, epicaptopril, fosinopril, fosinopril sodio, fosinoprilato, hemorfina-4, indolapril, indolaprilato, lisinopril, moveltipril, pentopril, perindopril, perindoprilato, quinapril, clorhidrato de quinapril, quinaprilato, ramipril, ramiprilato, espirapril, clorhidrato de espirapril, espiraprilato, trandolapril, trandolaprilato, zabicipril, zabiciprilato, zofenopril, zofenoprilato, dicho ARB se selecciona de entre el grupo que consiste en candesartán, cilexetilo, irbesartán, losartán, olmesartán, telmisartán, valsartán y pratosartán, dicho CCB se selecciona de entre el grupo que consiste en amlodipino, aranidipino, barnidipino, benidipino, cilnidipino, efonidipino, elgodipino, felodipino, isradipino, lacidipino, lercanidipino, manidipino, nicardipino, nifedipino, nilvadipino, nimodipino, nisoldipino, nitrendipino, diltiazem, clentiazem, bepridilo, benciclano, etafenona, flunarizina, lidoflazina, lomerizina, mibefradilo, fendilina, prenilamina, semotiadilo, terodilina, galopamilo y verapamilo, dicho derivado de estatina se selecciona de entre el grupo que consiste en lovastatina, mevastatina, pravastatina y simvastatina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
    imagen2
ES10747897.6T 2009-09-23 2010-09-03 Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1 Active ES2637024T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09425368 2009-09-23
EP09425368 2009-09-23
PCT/EP2010/062979 WO2011036047A1 (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Publications (1)

Publication Number Publication Date
ES2637024T3 true ES2637024T3 (es) 2017-10-10

Family

ID=41722750

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10747897.6T Active ES2637024T3 (es) 2009-09-23 2010-09-03 Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1

Country Status (25)

Country Link
US (1) US9492542B2 (es)
EP (1) EP2480224B1 (es)
JP (2) JP2013505278A (es)
KR (1) KR101774402B1 (es)
CN (1) CN102573827B (es)
AR (1) AR078307A1 (es)
AU (1) AU2010297405B2 (es)
BR (1) BR112012006149A2 (es)
CA (1) CA2760180C (es)
CY (1) CY1119125T1 (es)
DK (1) DK2480224T3 (es)
EA (1) EA021485B1 (es)
ES (1) ES2637024T3 (es)
GE (1) GEP20146067B (es)
HR (1) HRP20171209T1 (es)
HU (1) HUE033102T2 (es)
IL (1) IL218001A (es)
LT (1) LT2480224T (es)
MX (1) MX347957B (es)
PL (1) PL2480224T3 (es)
PT (1) PT2480224T (es)
SG (2) SG10201405408YA (es)
SI (1) SI2480224T1 (es)
UA (1) UA108742C2 (es)
WO (1) WO2011036047A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009624A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
AU2009221087B2 (en) 2008-03-07 2013-12-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US11221321B2 (en) * 2019-05-29 2022-01-11 Imam Abdulrahman Bin Faisal University Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof
WO2020261158A1 (en) 2019-06-25 2020-12-30 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK356085A (da) 1984-08-06 1986-02-07 Upjohn Co Reninhaemmende peptid eller et farmaceutisk acceptabelt syreadditionssalt deraf
MY103189A (en) 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
CA2023099A1 (en) 1989-09-04 1991-03-05 Quirico Branca Amino acid derivatives
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
TW198712B (es) 1991-04-17 1993-01-21 Hoffmann La Roche
IT1253703B (it) 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
SE9600120D0 (sv) 1996-01-15 1996-01-15 Astra Ab Novel medical use
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
JP2005501815A (ja) 2001-05-14 2005-01-20 メルク　エンド　カムパニー　インコーポレーテッド 治療方法
US20030060501A1 (en) 2001-09-19 2003-03-27 Francois Mach Facilitating tissue grafts with statins (HMG-COa reductase inhibitors)
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20070060549A1 (en) 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
WO2006046528A1 (ja) * 2004-10-29 2006-05-04 Kowa Co., Ltd. 糸球体疾患治療剤
EP1982710B1 (en) 2006-02-07 2013-12-18 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
WO2008084504A2 (en) 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
EP2481408A3 (en) * 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
AU2009221087B2 (en) 2008-03-07 2013-12-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
MX2010009624A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
PT2254869T (pt) 2008-03-07 2017-07-18 Acraf Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40

Also Published As

Publication number Publication date
GEP20146067B (en) 2014-03-25
KR20120090988A (ko) 2012-08-17
DK2480224T3 (en) 2017-09-04
EA021485B1 (ru) 2015-06-30
IL218001A (en) 2015-10-29
US20120220636A1 (en) 2012-08-30
SG178414A1 (en) 2012-03-29
UA108742C2 (uk) 2015-06-10
CY1119125T1 (el) 2018-02-14
SI2480224T1 (sl) 2017-10-30
LT2480224T (lt) 2017-08-25
WO2011036047A1 (en) 2011-03-31
CN102573827A (zh) 2012-07-11
AR078307A1 (es) 2011-10-26
PT2480224T (pt) 2017-07-18
AU2010297405B2 (en) 2016-05-26
CA2760180C (en) 2017-07-25
AU2010297405A1 (en) 2012-03-01
HUE033102T2 (en) 2017-11-28
JP6122470B2 (ja) 2017-04-26
SG10201405408YA (en) 2014-10-30
HRP20171209T1 (hr) 2017-10-20
PL2480224T3 (pl) 2017-10-31
CA2760180A1 (en) 2011-03-31
KR101774402B1 (ko) 2017-09-04
IL218001A0 (en) 2012-04-30
MX347957B (es) 2017-05-16
BR112012006149A2 (pt) 2016-06-28
EA201270449A1 (ru) 2012-08-30
EP2480224A1 (en) 2012-08-01
MX2012003485A (es) 2012-04-19
JP2016028026A (ja) 2016-02-25
CN102573827B (zh) 2016-08-31
JP2013505278A (ja) 2013-02-14
EP2480224B1 (en) 2017-05-24
US9492542B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
ES2637024T3 (es) Composición farmacéutica para el tratamiento de enfermedades inflamatorias mediadas por MCP-1
RU2014111474A (ru) Способы лечения сердечно-сосудистых нарушений
FIU20060451U0 (fi) Menetelmä alkoholin aiheuttaman annoksen vapautumisen vähentämiseksi optioidia viivästetysti vapauttavista oraalisista annostusmuodoista
ME01614B (me) Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primjenu
NZ595073A (en) Proline derivatives as cathepsin inhibitors
SG10201503828QA (en) N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors
ZA200810023B (en) Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
RU2006106451A (ru) Сложноэфирные соединения и их применение в медицине
WO2010068810A3 (en) Certain substituted amides, method of making, and method of use thereof
CA2514921A1 (en) Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension
RU2019126749A (ru) Композиции для лечения гипертензии
PE20080175A1 (es) Sales de malato, y polimorfos de acido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico
FR2954311B1 (fr) Procede de synthese perfectionne d'acroleine a partir de glycerol
FR2925331B1 (fr) Utilisation d'un hydrolysat de feve en tant que principe actif activateur de la synthese des aquaporines
AR096350A1 (es) Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular
RU2012151051A (ru) Фармацевтическая композиция и способ лечения гипертензии
JP2008063322A5 (es)
PE20130241A1 (es) Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal
MY160597A (en) Salts of isobutyric acid (1r*, 2r*, 4r*) -2- (2-{ [3- (4, 7-dimethoxy-1 h-benzoimidazol-2-yl) -methyl-amino } -ethyl) -5-phenyl-bicyclo [2.2.2] oct-5-en-2-yl ester
UA91073C2 (en) Process for the preparation of candesartan cilexetil
RU2023129881A (ru) Композиции для лечения гипертензии
TH78123B (th) สารออกฤทธิ์เชิงชีวภาพ 4h-เบนโซ[1,4] ออกซาซิน-3-โอน
UA15688S (uk) ЕТИКЕТКА ДЛЯ УПАКОВКИ ЛІКІВ «ДОЛАРЕН» (НА 50х4 ТАБЛЕТКИ)
TH86760B (th) การรวมกันที่รักษาโรคได้ ซึ่งประกอบด้วยตัวบล็อกช่องแคลเซียมชนิดไดไฮโดรไพริดีนที่ออกฤทธิ์ระยะยาว และสเททิน
UA17214S (uk) Упаковка для профілактичного засобу «капсули для чоловіків «вогонь бажань»